Holen Sie sich die Stockscreener-App
8.82
25.46%
1.79
Schlusskurs vom Vortag:
$7.03
Offen:
$8.53
24-Stunden-Volumen:
23.74M
Relative Volume:
17.93
Marktkapitalisierung:
$521.23M
Einnahmen:
$192.64M
Nettoeinkommen (Verlust:
$2.51M
KGV:
168.32
EPS:
0.0524
Netto-Cashflow:
$12.42M
1W Leistung:
+27.64%
1M Leistung:
+64.55%
6M Leistung:
+86.86%
1J Leistung:
+84.13%
1-Tages-Spanne:
$8.50
$9.60
1-Wochen-Bereich:
$6.87
$9.60
52-Wochen-Spanne:
$3.8092
$9.60
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Vergleichen Sie VNDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
8.82 | 415.45M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Eingeleitet | B. Riley Securities | Buy |
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
Vanda wins FDA approval for NEREUS motion sickness drug - MSN
Vanda stock jumps with FDA approval of motion sickness drug - BioWorld MedTech
Vanda Pharmaceuticals hits 3-year high after FDA approves Nereus | Tap to know more | Inshorts - Inshorts
D.C.-based Vanda gets FDA nod for motion-sickness treatment - The Business Journals
What's Going On With Vanda Pharmaceuticals Stock Wednesday? - Benzinga
Vanda Pharmaceuticals: Could Now Be A Good Time To Invest? - StocksToTrade
Vanda surges 28% after FDA approval - breakingthenews.net
B. Riley Securities Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Raises Target Price to $14 - 富途牛牛
B. Riley Securities Raises Price Target for VNDA to $14.00 Maint - GuruFocus
Vanda Pharmaceuticals price target raised to $14 from $11 at B Riley - MSN
Vanda Pharmaceuticals Inc. (VNDA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vanda Pharmaceuticals (NASDAQ:VNDA) Hits New 52-Week HighHere's What Happened - MarketBeat
Vanda Pharma's (VNDA) NEREUS Approval Boosts Growth Prospects - GuruFocus
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy - GuruFocus
Vanda Pharmaceuticals Stock Jumps After FDA Approves Motion Sickness Drug - Barron's
Vanda Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies - TipRanks
Biggest Mover Wednesday: Vanda's FDA Win Sends the Stock Flying - GuruFocus
Biggest stock movers Wednesday: Vanda Pharmaceuticals and Cybin - MSN
Vanda Pharmaceuticals Stock Rockets: Time to Ride the Wave? - timothysykes.com
FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus - Pharmaceutical Technology
Vanda Pharmaceuticals (VNDA) Surges 21% on FDA Approval of Motion Sickness Drug - GuruFocus
Vanda Pharmaceuticals stock soars after FDA approval of motion sickness drug - Investing.com
VNDA: Jefferies Maintains Hold Rating, Raises Price Target to $7.50 | VNDA Stock News - GuruFocus
B. Riley Raises Price Target on Vanda Pharmaceuticals to $14 Form $11, Keeps Buy Rating - marketscreener.com
Vanda Pharmaceuticals surges as FDA approves motion sickness drug - Sharecast.com
Market news - investments.halifax.co.uk
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains - Yahoo Finance
Vanda Pharmaceuticals (VNDA) Gains FDA Nod for Motion Sickness D - GuruFocus
Stock Movers: VANDA PHARMACEUTICALS , NIKE , SPX - Bloomberg.com
Vanda Wins FDA Approval for NEREUS Motion Sickness Drug - TipRanks
Jefferies raises Vanda Pharmaceuticals stock price target on motion sickness drug potential - Investing.com
Why Is VNDA Stock Surging Premarket? FDA Approves Motion Sickness Drug - Tokenist
Vanda Pharmaceuticals (VNDA) Surges on FDA Approval - GuruFocus
FDA Greenlights Vanda Pharmaceuticals' (VNDA) New Motion Sicknes - GuruFocus
Vanda Pharmaceuticals (VNDA) Shares Surge Following FDA Approval - GuruFocus
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades - ts2.tech
Trending tickers: latest investor updates on Nvidia, Caterpillar, Vanda Pharmaceuticals and Walker Crips - Yahoo Finance UK
Stock Market Today: S&P 500, Dow Jones Futures Down As Santa Rally Hopes Fade—Investors Await Initial Jobless Claims Report - Benzinga
US FDA approves Vanda Pharmaceuticals’ motion sickness drug - WTVB
Why Is Vanda Pharmaceuticals' (VNDA) Stock Trending Overnight? - Benzinga
US FDA approves Vanda Pharmaceuticals' motion sickness drug - ETPharma.com
US FDA approves Vanda Pharmaceuticals’ motion sickness drug By Reuters - Investing.com
US FDA Approves Vanda Pharmaceuticals' Motion Sickness Drug - U.S. News & World Report
Vanda Pharmaceuticals announces FDA approval of Nereus (tradipitant) - marketscreener.com
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - Nasdaq
3 Biotech Stocks With Major 2026 Catalysts - Yahoo Finance
The Christmas party is still ongoing in these stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - MSN
The Christmas Party Is Still Ongoing In These Stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - Asianet Newsable
Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock - Stocktwits
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vanda Pharmaceuticals Inc-Aktie (VNDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | Director |
Jun 13 '25 |
Sale |
4.59 |
7,000 |
32,130 |
97,082 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):